@article {Sarfraz2020.08.21.20179200, author = {Azza Sarfraz and Zouina Sarfraz and Marcos Sanchez-Gonzalez and Jack Michel and George Michel and Odalys Frontela and Jorge Posado and Jose Cardona and Eugonia Angueira}, title = {Randomized Controlled Trials of Remdesivir in Hospitalized COVID-19 Patients: A Systematic Review and Meta-Analysis}, elocation-id = {2020.08.21.20179200}, year = {2020}, doi = {10.1101/2020.08.21.20179200}, publisher = {Cold Spring Harbor Laboratory Press}, abstract = {Background The first cases of the coronavirus disease 2019 (COVID-19) were reported in Wuhan, China. No antiviral treatment options are currently available with proven clinical efficacy. However, preliminary findings from phase III trials suggest that remdesivir is an effective and safe treatment option for COVID-19 patients with both moderate and severe disease.Objective The aim of the present meta-analysis was to investigate whether remdesivir was effective for treating COVID-19 including reduced in-hospital adverse events, oxygen support, and mortality rates.Methods According to PRISMA reporting guidelines, a review was conducted from January 1 2020 until 25 August 2020 with MeSH terms including COVID-19, COVID, coronavirus, SARS-CoV-2, remdesivir, adenosine nucleoside triphosphate analog, Veklury using MEDLINE, Scopus, and CINAHL Plus. A modified Delphi process was utilized to include the studies and ensure that the objectives were addressed. Using dichotomous data for select values, the unadjusted odds ratios (ORs) were calculated applying Mantel Haenszel (M-H) random-effects method in Review Manager 5.4.Results Randomized controlled trials pooled in 3013 participants with 46.3\% (n=1,395) in the remdesivir group and 53.7\% (n=1,618) in the placebo group. The placebo group had a higher risk of mortality as compared to the intervention group with significant odds ratio (OR=0.61) (95\% confidence interval of 0.45 0.82; P=0.001). There was minimal heterogeneity among the studies (I2=0\%).Conclusions Our findings suggest that remdesivir extends clinical benefits by reducing mortality, adverse events and oxygen support in moderate to severely ill COVID-19 patients. Concerted efforts and further randomized placebo-controlled trials are warranted to examine the potency of antiviral drugs and immune-pathological host responses contributing to severity of COVID-19.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo funding was received for this study.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Division of Clinical \& Translational Research at Larkin Community Hospital was the oversight body that provided approval for the research.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data that support the findings of this study are openly available in Medline or journal sites including the Lancet, New England Journal of Medicine with 10.1093/cid/ciaa1041; 10.1056/NEJMoa2007764; 10.1016/S0140-6736(20)31022-9. https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciaa1041/5876045$\#$:~:text=In\%20this\%20comparative\%20analysis\%2C\%20by,patients\%20with\%20severe\%20COVID\%2D19. https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)31022-9/fulltext}, URL = {https://www.medrxiv.org/content/early/2020/09/05/2020.08.21.20179200}, eprint = {https://www.medrxiv.org/content/early/2020/09/05/2020.08.21.20179200.full.pdf}, journal = {medRxiv} }